1
|
Markousis-Mavrogenis G, Minich WB, Al-Mubarak AA, Anker SD, Cleland JGF, Dickstein K, Lang CC, Ng LL, Samani NJ, Zannad F, Metra M, Seemann P, Hoeg A, Lopez P, van Veldhuisen DJ, de Boer RA, Voors AA, van der Meer P, Schomburg L, Bomer N. Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. Cardiovasc Res 2023; 119:1690-1705. [PMID: 36883593 PMCID: PMC10325696 DOI: 10.1093/cvr/cvad042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 01/11/2023] [Accepted: 01/21/2023] [Indexed: 03/09/2023] Open
Abstract
AIMS The importance of autoantibodies (AABs) against adrenergic/muscarinic receptors in heart failure (HF) is not well-understood. We investigated the prevalence and clinical/prognostic associations of four AABs recognizing the M2-muscarinic receptor or the β1-, β2-, or β3-adrenergic receptor in a large and well-characterized cohort of patients with HF. METHODS AND RESULTS Serum samples from 2256 patients with HF from the BIOSTAT-CHF cohort and 299 healthy controls were analysed using newly established chemiluminescence immunoassays. The primary outcome was a composite of all-cause mortality and HF rehospitalization at 2-year follow-up, and each outcome was also separately investigated. Collectively, 382 (16.9%) patients and 37 (12.4%) controls were seropositive for ≥1 AAB (P = 0.045). Seropositivity occurred more frequently only for anti-M2 AABs (P = 0.025). Amongst patients with HF, seropositivity was associated with the presence of comorbidities (renal disease, chronic obstructive pulmonary disease, stroke, and atrial fibrillation) and with medication use. Only anti-β1 AAB seropositivity was associated with the primary outcome [hazard ratio (95% confidence interval): 1.37 (1.04-1.81), P = 0.024] and HF rehospitalization [1.57 (1.13-2.19), P = 0.010] in univariable analyses but remained associated only with HF rehospitalization after multivariable adjustment for the BIOSTAT-CHF risk model [1.47 (1.05-2.07), P = 0.030]. Principal component analyses showed considerable overlap in B-lymphocyte activity between seropositive and seronegative patients, based on 31 circulating biomarkers related to B-lymphocyte function. CONCLUSIONS AAB seropositivity was not strongly associated with adverse outcomes in HF and was mostly related to the presence of comorbidities and medication use. Only anti-β1 AABs were independently associated with HF rehospitalization. The exact clinical value of AABs remains to be elucidated.
Collapse
Affiliation(s)
- George Markousis-Mavrogenis
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Waldemar B Minich
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany
- ImmunometriX GmbH i.L, Brandenburgische Str. 83, D-10713 Berlin, Germany
| | - Ali A Al-Mubarak
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Stefan D Anker
- Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Charitépl. 1, 10117 Berlin, Germany
| | - John G F Cleland
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK
- National Heart & Lung Institute, Imperial College, Guy Scadding Building, Dovehouse St, London SW3 6LY, UK
| | - Kenneth Dickstein
- University of Bergen, Stavanger University Hospital, Gerd-Ragna Bloch Thorsens gate 8, 4011 Stavanger, Norway
| | - Chim C Lang
- Division of Molecular & Clinical Medicine, University of Dundee, Nethergate, Dundee DD1 4HN, UK
| | - Leong L Ng
- Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Groby Rd, Leicester LE3 9QP, UK
- NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Groby Rd, Leicester LE3 9QP, UK
| | - Nilesh J Samani
- University of Bergen, Stavanger University Hospital, Gerd-Ragna Bloch Thorsens gate 8, 4011 Stavanger, Norway
| | - Faiez Zannad
- Université de Lorraine, Inserm CIC 1403, CHRU, Cité Universitaire, 57000 Metz, France
| | - Marco Metra
- Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza del Mercato, 15, 25121 Brescia BS, Italy
| | - Petra Seemann
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany
- ImmunometriX GmbH i.L, Brandenburgische Str. 83, D-10713 Berlin, Germany
| | - Antonia Hoeg
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany
| | - Patricio Lopez
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany
- ImmunometriX GmbH i.L, Brandenburgische Str. 83, D-10713 Berlin, Germany
| | - Dirk J van Veldhuisen
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Rudolf A de Boer
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Adriaan A Voors
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Peter van der Meer
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Lutz Schomburg
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Hessische Straß0065 4A, CCM, Berlin D-10115, Germany
| | - Nils Bomer
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | | |
Collapse
|
2
|
Sun H, Li X, Yuan H, Wang C, Zhang G, Shi H. Comparative study of disease progression for heart failure with different etiologies via time-ordered network analysis. Am J Transl Res 2022; 14:6604-6617. [PMID: 36247267 PMCID: PMC9556474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Accepted: 08/04/2022] [Indexed: 06/16/2023]
Abstract
OBJECTIVES Heart failure (HF), the primary end-stage manifestation of multiple cardiovascular diseases, has become a global epidemic with high morbidity and mortality. However, the mechanisms underlying the pathogenesis of HF with different etiologies have yet to be fully elucidated. METHODS In this study, we developed a novel method to determine the dysregulated lncRNA-mRNA regulation pairs (LMRPs) in the different causes that lead to HF. Time-ordered dysregulated lncRNA-mRNA regulation networks were constructed for comparing the HF progression initiated from different causes. Additionally, the random forest and support vector machine classification algorithm were applied to identify HF-related diagnostic biomarkers. RESULTS Biological functional analysis indicated that similar functions were detected at the late stage across different causes of HF, whereas different characteristics were revealed during disease progression. Specifically, the disturbance of myocardial energy metabolism might be a cause of dilated cardiomyopathy (DCM) and peripartum cardiomyopathy (PPCM), while immune response appeared earlier in hypertrophic cardiomyopathy (HCM). Inflammatory response during HCM and PPCM progression might be mediated by complement system, whereas ischemic cardiomyopathy (ICM) might be induced by cytokines. Finally, we identified several panels of diagnostic biomarkers for distinguishing HF patients of different etiologies from non-heart failure (NF) controls. CONCLUSIONS This study revealed distinct functional characteristics during the progression of HF from different causes and facilitated the discovery of candidate diagnostic biomarkers for HF.
Collapse
Affiliation(s)
- Haoran Sun
- College of Bioinformatics Science and Technology, Harbin Medical UniversityHarbin, Heilongjiang Province, China
| | - Xiuhong Li
- College of Bioinformatics Science and Technology, Harbin Medical UniversityHarbin, Heilongjiang Province, China
| | - Hao Yuan
- College of Bioinformatics Science and Technology, Harbin Medical UniversityHarbin, Heilongjiang Province, China
| | - Chengyi Wang
- College of Bioinformatics Science and Technology, Harbin Medical UniversityHarbin, Heilongjiang Province, China
| | - Guangde Zhang
- Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical UniversityHarbin, Heilongjiang Province, China
| | - Hongbo Shi
- College of Bioinformatics Science and Technology, Harbin Medical UniversityHarbin, Heilongjiang Province, China
| |
Collapse
|
3
|
Atractylenolide III Attenuates Apoptosis in H9c2 Cells by Inhibiting Endoplasmic Reticulum Stress through the GRP78/PERK/CHOP Signaling Pathway. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2022; 2022:1149231. [PMID: 36159560 PMCID: PMC9492373 DOI: 10.1155/2022/1149231] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Accepted: 08/02/2022] [Indexed: 12/04/2022]
Abstract
The objective of this study was to determine the effect of atractylenolide III (ATL-III) on endoplasmic reticulum stress (ERS) injury, H9c2 cardiomyocyte apoptosis induced by tunicamycin (TM), and the GRP78/PERK/CHOP signaling pathway. Molecular docking was applied to predict the binding affinity of ATL-III to the key proteins GRP78, PERK, IREα, and ATF6 in ERS. Then, in vitro experiments were used to verify the molecular docking results. ERS injury model of H9c2 cells was established by TM. Cell viability was detected by MTT assay, and apoptosis was detected by Hoechst/PI double staining and flow cytometry. Protein expression levels of GRP78, PERK, eIF2α, ATF4, CHOP, Bax, Bcl-2, and Caspase-3 were detected by Western blot. And mRNA levels of GRP78, CHOP, PERK, eIF2α, and ATF4 were detected by RT-qPCR. Moreover, the mechanism was further studied by using GRP78 inhibitor (4-phenylbutyric acid, 4-PBA), and PERK inhibitor (GSK2656157). The results showed that ATL-III had a good binding affinity with GRP78, and the best binding affinity was with PERK. ATL-III increased the viability of H9c2 cells, decreased the apoptosis rate, downregulated Bax and Caspase-3, and increased Bcl-2 compared with the model group. Moreover, ATL-III downregulated the protein and mRNA levels of GRP78, CHOP, PERK, eIF2α, and ATF4, consistent with the inhibition of 4-PBA. ATL-III also decreased the expression levels of PERK, eIF2α, ATF4, CHOP, Bax, and Caspase-3, while increasing the expression of Bcl-2, which is consistent with GSK2656157. Taken together, ATL-III could inhibit TM-induced ERS injury and H9c2 cardiomyocyte apoptosis by regulating the GRP78/PERK/CHOP signaling pathway and has myocardial protection.
Collapse
|